Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortosiran in Prior VTE and High-Risk Cancer Patients
NCT07850453Phase 2Not yet recruiting
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 4
01
Overview
A Phase 2 trial of vortosiran in venous thromboembolism (VTE), sponsored by Ribocure Pharmaceuticals AB. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
vortosiran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07850453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850453.